Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palisade Bio ( (PALI) ) has issued an update.
On September 26, 2025, Palisade Bio, Inc. attempted to hold a special meeting of stockholders, but it was adjourned due to insufficient quorum. The meeting is rescheduled for October 10, 2025, with no changes to the proposals to be voted on. Stockholders who have already voted do not need to take further action unless they wish to change their vote.
The most recent analyst rating on (PALI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Average Trading Volume: 2,408,616
Technical Sentiment Signal: Sell
Current Market Cap: $6.24M
Learn more about PALI stock on TipRanks’ Stock Analysis page.